新型雌激素受体GPR30抑制子宫肌瘤平滑肌细胞的增殖  

G-protein-coupled Estrogen Receptor-30 Inhibit the Proliferation of Human Uterine Leiomyoma

作　　者：田瑞娟[1] 王利凤[1] 王增勇[2] 许丽娟[1] 王悦冰[1] 李洋[3] 石岩蓉[3] 朱颖军[4] 林婉君[4] 李董[1] 

机构地区：[1]南开大学医学院,天津300071 [2]南开大学药学院,天津300071 [3]天津医科大学,天津300192 [4]天津市中心妇产科医院,天津300199

出　　处：《南开大学学报（自然科学版）》2014年第3期16-21,共6页Acta Scientiarum Naturalium Universitatis Nankaiensis

基　　金：国家重大科学研究计划(2011CB944003)

摘　　要：子宫肌瘤是女性生殖器最常见的一种良性肿瘤,是由子宫平滑肌细胞异常增殖形成的,故又称为子宫平滑肌瘤.GPR30是新型雌激素偶联G蛋白受体,在乳腺癌的发生发展中起到重要作用,但是在子宫肌瘤疾病中的作用未见报道.对取自临床病人样本的子宫肌瘤和周边正常子宫肌组织,分离其平滑肌细胞,通过应用Western blot、real-time PCR(RT-qPCR)、免疫荧光等技术,验证GPR30对其增殖的影响.结果表明,在子宫肌瘤组织和子宫肌瘤平滑肌细胞中,GPR30的mRNA和蛋白的表达水平显著高于周边的正常子宫肌组织和子宫肌平滑肌细胞.在子宫肌瘤平滑肌细胞中,GPR30的特异性激动剂G-1,可以激活表皮生长因子受体EGFR,抑制细胞的增殖.这为子宫肌瘤的研究与治疗提供了新视角,具有重要的理论和实际意义.Human uterine leiomyoma, the most common benign tumor in premenopausal women, derived from the deregulated proliferation of uterine smooth muscle cells. It has reported that GPR30 is new estrogen G protein-coupled receptor, which is very important in development of breast cancer. However, the effect of GPR30 in human uterine leiomyoma is unknown untill now. By western blot, RT-qPCR and immunostaining assay, we found that GPR30 was highly expressed in uterine leiomyomas compared with their matched myometrium. GPR30 protein and mRNA were much higher in smooth muscle cells （SMCs） derived from leiomyoma tissues than myometrium. Treatment with G-1, a GPR30 agonist, stimulated phosphorylation of epithelial growth factor receptor （EGFR） in uterine leiomyoma SMCs and inhibited the proliferation of uterine leiomyoma SMCs. It may provide a new perspective for the study and treatment of uterine leiomyoma.

关 键 词：雌激素受体 GPR30 子宫肌瘤 平滑肌 

分 类 号：R730.5[医药卫生—肿瘤]